Philip J. Nicklin
YOU?
Author Swipe
View article: Supplementary Table S4 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S4 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma Open
Supplementary Table S4. Clinical Characteristics and Tumor Volume Growth During Active Surveillance.
View article: Supplementary Figure S2 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Figure S2 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma Open
Supplementary Figure S2. Tumor volume growth rates and respective genomics.
View article: Supplementary Figure S1 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Figure S1 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma Open
Supplementary Figure S1. Somatic genomic alterations in the cohort of IDH-mutant gliomas.
View article: Supplementary Table S2 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S2 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma Open
Supplementary Table S2. Baseline Radiological Characteristics Overall and Stratified by 1p19q Status.
View article: Supplementary Table S3 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S3 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma Open
Supplementary Table S3. Baseline Radiological Characteristics Stratified by Molecular Grade.
View article: Data from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Data from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma Open
Purpose:Isocitrate dehydrogenase–mutant (IDH-mt) gliomas are incurable primary brain tumors characterized by a slow-growing phase over several years followed by a rapid-growing malignant phase. We hypothesized that tumor volume growth rate…
View article: Supplementary Table S1 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S1 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma Open
Supplementary Table S1. Alterations in Molecular-Grade High Group IDH-mutant Gliomas.
View article: Supplementary Figure S3 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Figure S3 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma Open
Supplementary Figure S3. Next-Intervention-Free Survival and overall survival.
View article: Data from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Data from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma Open
Purpose:Isocitrate dehydrogenase–mutant (IDH-mt) gliomas are incurable primary brain tumors characterized by a slow-growing phase over several years followed by a rapid-growing malignant phase. We hypothesized that tumor volume growth rate…
View article: Supplementary Table S2 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S2 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma Open
Supplementary Table S2. Baseline Radiological Characteristics Overall and Stratified by 1p19q Status.
View article: Supplementary Table S1 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S1 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma Open
Supplementary Table S1. Alterations in Molecular-Grade High Group IDH-mutant Gliomas.
View article: Supplementary Table S4 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S4 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma Open
Supplementary Table S4. Clinical Characteristics and Tumor Volume Growth During Active Surveillance.
View article: Supplementary Table S3 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S3 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma Open
Supplementary Table S3. Baseline Radiological Characteristics Stratified by Molecular Grade.
View article: Supplementary Figure S3 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Figure S3 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma Open
Supplementary Figure S3. Next-Intervention-Free Survival and overall survival.
View article: Supplementary Figure S1 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Figure S1 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma Open
Supplementary Figure S1. Somatic genomic alterations in the cohort of IDH-mutant gliomas.
View article: Supplementary Figure S2 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Figure S2 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma Open
Supplementary Figure S2. Tumor volume growth rates and respective genomics.
View article: Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma Open
Purpose: Isocitrate dehydrogenase–mutant (IDH-mt) gliomas are incurable primary brain tumors characterized by a slow-growing phase over several years followed by a rapid-growing malignant phase. We hypothesized that tumor volume growth rat…
View article: NIMG-38. TUMOR VOLUME GROWTH RATES AND DOUBLING TIMES DURING ACTIVE SURVEILLANCE OF IDH-MUTANT LOW-GRADE GLIOMA
NIMG-38. TUMOR VOLUME GROWTH RATES AND DOUBLING TIMES DURING ACTIVE SURVEILLANCE OF IDH-MUTANT LOW-GRADE GLIOMA Open
PURPOSE Isocitrate-dehydrogenase-mutant (IDH-mt) gliomas are incurable primary brain tumors characterized by a slow-growing phase over several years followed by a rapid-growing malignant phase. We hypothesized that tumor volume growth rate…
View article: Detection of cutaneous oxygen saturation using a novel snapshot hyperspectral camera: a feasibility study
Detection of cutaneous oxygen saturation using a novel snapshot hyperspectral camera: a feasibility study Open
This pilot study demonstrated the feasibility of a snapshot hyperspectral camera for detecting quantitative physiological changes in cutaneous StO2 in normal human volunteers, and serves as a precursor for further validation in perioperati…
View article: Preclinical and first-in-human-brain-cancer applications of [18F]poly-(ADP-ribose) polymerase inhibitor PET/MR
Preclinical and first-in-human-brain-cancer applications of [18F]poly-(ADP-ribose) polymerase inhibitor PET/MR Open
We report pre-clinical and first-in-human-brain-cancer data using a targeted poly(ADP-ribose)polymerase1 (PARP1) binding PET tracer, [ 18 F]PARPi, as a diagnostic tool to differentiate between brain cancers and treatment related changes. I…
View article: Preclinical and first-in-human-brain-cancer applications of [18F]poly (ADP-ribose) polymerase inhibitor PET/MR
Preclinical and first-in-human-brain-cancer applications of [18F]poly (ADP-ribose) polymerase inhibitor PET/MR Open
Background We report preclinical and first-in-human-brain-cancer data using a targeted poly (ADP-ribose) polymerase 1 (PARP1) binding PET tracer, [18F]PARPi, as a diagnostic tool to differentiate between brain cancers and treatment-related…